NASDAQ:ZLAB

Zai Lab Competitors

$164.48
+7.01 (+4.45 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$156.48
Now: $164.48
$165.75
50-Day Range
$125.11
MA: $139.02
$164.83
52-Week Range
$58.59
Now: $164.48
$193.54
Volume965,577 shs
Average Volume471,913 shs
Market Capitalization$14.57 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Competitors

Zai Lab (NASDAQ:ZLAB) Vs. VRTX, TAK, REGN, ALXN, BGNE, and RPRX

Should you be buying ZLAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Zai Lab, including Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), and Royalty Pharma (RPRX).

Vertex Pharmaceuticals (NASDAQ:VRTX) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Vertex Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Zai LabN/AN/AN/A

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.43$1.18 billion$4.2950.34
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28

Vertex Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Vertex Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Zai Lab00503.00

Vertex Pharmaceuticals presently has a consensus price target of $293.2083, suggesting a potential upside of 35.76%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Vertex Pharmaceuticals' higher probable upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Zai Lab.

Summary

Vertex Pharmaceuticals beats Zai Lab on 12 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Takeda Pharmaceutical and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Zai LabN/AN/AN/A

Earnings & Valuation

This table compares Takeda Pharmaceutical and Zai Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.78$407.02 million$1.789.56
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28

Takeda Pharmaceutical has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Takeda Pharmaceutical and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical02002.00
Zai Lab00503.00

Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Takeda Pharmaceutical.

Summary

Takeda Pharmaceutical beats Zai Lab on 8 of the 13 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares Regeneron Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Zai LabN/AN/AN/A

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.68$2.12 billion$21.4722.84
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28

Regeneron Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Regeneron Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Zai Lab00503.00

Regeneron Pharmaceuticals presently has a consensus price target of $644.1739, suggesting a potential upside of 31.35%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Regeneron Pharmaceuticals' higher probable upside, research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Zai Lab.

Summary

Regeneron Pharmaceuticals beats Zai Lab on 12 of the 15 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Zai Lab (NASDAQ:ZLAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Zai Lab shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Alexion Pharmaceuticals and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Zai LabN/AN/AN/A

Earnings & Valuation

This table compares Alexion Pharmaceuticals and Zai Lab's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.42$2.40 billion$9.7417.21
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28

Alexion Pharmaceuticals has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Alexion Pharmaceuticals and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Zai Lab00503.00

Alexion Pharmaceuticals presently has a consensus price target of $153.4286, suggesting a potential downside of 8.48%. Zai Lab has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts clearly believe Zai Lab is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Zai Lab on 11 of the 15 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Risk and Volatility

Zai Lab has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

Insider & Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Zai Lab and BeiGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
BeiGene-569.22%-56.81%-39.93%

Earnings and Valuation

This table compares Zai Lab and BeiGene's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28
BeiGene$428.21 million66.61$-948,630,000.00($15.80)-19.69

Zai Lab has higher earnings, but lower revenue than BeiGene. Zai Lab is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zai Lab and BeiGene, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00503.00
BeiGene21602.44

Zai Lab presently has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. BeiGene has a consensus price target of $319.3750, suggesting a potential upside of 2.67%. Given Zai Lab's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zai Lab is more favorable than BeiGene.

Summary

Zai Lab beats BeiGene on 10 of the 14 factors compared between the two stocks.

Zai Lab (NASDAQ:ZLAB) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Insider & Institutional Ownership

81.3% of Zai Lab shares are owned by institutional investors. Comparatively, 40.9% of Royalty Pharma shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Zai Lab and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zai LabN/AN/AN/A
Royalty PharmaN/AN/AN/A

Earnings and Valuation

This table compares Zai Lab and Royalty Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$12.98 million1,122.62$-195,070,000.00($3.03)-54.28
Royalty PharmaN/AN/AN/AN/AN/A

Royalty Pharma has lower revenue, but higher earnings than Zai Lab.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zai Lab and Royalty Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zai Lab00503.00
Royalty Pharma05402.44

Zai Lab presently has a consensus price target of $197.8460, suggesting a potential upside of 20.29%. Royalty Pharma has a consensus price target of $51.8750, suggesting a potential upside of 20.05%. Given Zai Lab's stronger consensus rating and higher probable upside, equities research analysts plainly believe Zai Lab is more favorable than Royalty Pharma.

Summary

Zai Lab beats Royalty Pharma on 5 of the 6 factors compared between the two stocks.


Zai Lab Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$215.98+1.8%$55.90 billion$4.16 billion27.27Upcoming Earnings
Analyst Revision
News Coverage
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.02+0.6%$53.71 billion$30.20 billion56.74Analyst Downgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$490.43+3.3%$52.54 billion$7.86 billion17.93
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$167.65+0.5%$37.04 billion$4.99 billion39.17
BeiGene logo
BGNE
BeiGene
1.1$311.06+2.9%$28.52 billion$428.21 million-15.39Analyst Downgrade
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$43.21+1.0%$26.23 billionN/A0.00
Genmab A/S logo
GMAB
Genmab A/S
1.4$36.84+0.8%$24.16 billion$804.57 million28.56Analyst Report
CureVac logo
CVAC
CureVac
0.7$114.10+1.0%$21.33 billionN/A0.00Analyst Upgrade
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$94.15+0.6%$21.10 billion$1.30 billion25.72
Catalent logo
CTLT
Catalent
1.7$113.21+1.7%$19.27 billion$3.09 billion72.11
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.77+0.2%$16.16 billion$219.75 million-17.60Upcoming Earnings
Analyst Report
Insider Selling
Analyst Revision
News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.70+0.5%$14.49 billion$1.70 billion18.24Upcoming Earnings
Insider Selling
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.56+2.1%$14.45 billion$3.07 billion-53.61Analyst Report
Grifols logo
GRFS
Grifols
1.3$18.60+2.5%$12.79 billion$5.71 billion16.61Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$68.70+1.3%$11.42 billion$2.32 billion56.78
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.20+0.5%$11.14 billion$16.89 billion-2.77Upcoming Earnings
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$29.47+0.3%$10.48 billion$8.60 billion-5.41
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$167.52+1.4%$9.44 billion$2.16 billion52.85Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$209.33+1.2%$9.32 billion$1.45 billion19.80
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$35.83+1.0%$9.23 billionN/A0.00Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.90+1.1%$8.27 billion$40.56 million-16.39
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$160.84+0.3%$8.26 billion$3.34 million-20.89
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$70.99+2.8%$7.37 billion$87.99 million-84.51
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.6$108.87+0.2%$7.29 billion$103.71 million-24.80
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$131.85+5.2%$7.09 billion$14.98 million-16.06Analyst Downgrade
Unusual Options Activity
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.47+0.0%$6.85 billion$311.33 million-127.02Analyst Downgrade
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.46+2.3%$5.98 billion$1.12 billion88.46
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.09+0.9%$5.78 billion$150,000.00-19.38Analyst Report
Analyst Revision
Allakos logo
ALLK
Allakos
1.7$107.16+1.7%$5.73 billionN/A-39.11
Perrigo logo
PRGO
Perrigo
2.3$42.63+0.2%$5.69 billion$4.84 billion-710.38Upcoming Earnings
Dividend Announcement
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.38+1.1%$5.67 billion$380.83 million-9.13
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$94.40+0.5%$5.47 billion$66.51 million17.42
Galapagos logo
GLPG
Galapagos
1.3$82.44+0.8%$5.40 billion$1.00 billion-12.49Analyst Report
Schrödinger logo
SDGR
Schrödinger
1.5$73.26+1.1%$5.13 billion$85.54 million0.00Insider Selling
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.21+0.2%$4.67 billionN/A-6.13
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.72+0.5%$4.36 billion$6.87 million-7.22Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.75+0.3%$4.33 billion$204.89 million-37.19
I-Mab logo
IMAB
I-Mab
1.2$58.42+4.3%$4.20 billion$4.31 million-2.02Gap Down
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.81+1.4%$4.03 billion$806.43 million-9.46
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.19+0.1%$3.85 billion$117.91 million-11.19Upcoming Earnings
Insider Selling
LEGN
Legend Biotech
1.2$28.28+3.6%$3.76 billion$64.39 million0.00
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.07+0.2%$3.70 billionN/A-6.21Upcoming Earnings
Analyst Report
Insider Selling
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10+1.8%$3.66 billion$114.62 million-8.10
Insmed logo
INSM
Insmed
1.2$35.02+3.5%$3.62 billion$136.47 million-13.47Upcoming Earnings
Analyst Downgrade
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.31+0.1%$3.60 billionN/A-20.89
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$63.12+4.6%$3.38 billion$1.11 billion20.30Upcoming Earnings
Gap Up
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.87+2.9%$3.34 billion$339.08 million-12.13Analyst Revision
Alkermes logo
ALKS
Alkermes
1.2$20.92+2.0%$3.33 billion$1.17 billion-45.48Upcoming Earnings
Insider Selling
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.51+0.8%$3.31 billion$26.52 million-8.06News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.82+1.8%$3.29 billion$306.98 million-6.70
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.